Print

Talecris Biotherapeutics (TLCR) (JOBS) Plans IPO  
9/15/2009 6:36:54 AM

Bookmark and Share

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics Holdings Corp. (“Talecris”) today announced the launch of its initial public offering of 44,736,842 shares of its common stock, par value $0.01 per share. Talecris is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, neurology, pulmonology and hemostasis.

Of the shares being offered, 28,947,368 are being offered by Talecris and 15,789,474 are being offered by the selling stockholder, Talecris Holdings, LLC. Talecris Holdings, LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and limited partnerships affiliated with Ampersand Ventures. The initial public offering price is expected to be between $18.00 and $20.00 per share. Talecris has applied to have the shares of common stock approved for quotation on The Nasdaq Global Market under the ticker symbol “TLCR.” The underwriters have the option to purchase from the selling stockholder up to an additional 6,710,526 shares of common stock, on the same terms and conditions.

Talecris intends to use the net proceeds of the offering to repay amounts owed under its First Lien Term Loan Credit Agreement and Second Lien Term Loan Credit Agreement. Talecris will not receive any of the proceeds from the offering of the common stock by the selling stockholder.

Morgan Stanley, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. are acting as joint book-running managers for the proposed offering. Wells Fargo Securities, LLC, Barclays Capital Inc. and UBS Investment Bank are acting as co-managers.

Copies of the preliminary prospectus relating to the offering may be obtained by contacting: Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014, telephone 1-866-718-1649 or by emailing prospectus@morganstanley.com; Goldman, Sachs & Co., Prospectus Department, 85 Broad Street, New York, New York 10004, telephone 1-866-471-2526, facsimile 1-212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Citigroup Global Markets Inc. at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, telephone 1-800-831-9146; or J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, Attention: Prospectus Department, telephone 718-242-8002.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any such offer or solicitation or any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:

Talecris Corporate Communications Becky Levine, 919-316-6590 becky.levine@talecris.com or Brunswick Group Susan Stillings / Greg Faje, 212-333-3810

//-->